Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
about
The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature ReviewReporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic ReviewClinical trial transparency: many gains but access to evidence for new medicines remains imperfect.Industry - from sponsor to provider?Alternative package leaflets improve people's understanding of drug side effects-A randomized controlled exploratory survey
P2860
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Information on new drugs at ma ...... cations, and registry reports.
@ast
Information on new drugs at ma ...... cations, and registry reports.
@en
type
label
Information on new drugs at ma ...... cations, and registry reports.
@ast
Information on new drugs at ma ...... cations, and registry reports.
@en
prefLabel
Information on new drugs at ma ...... cations, and registry reports.
@ast
Information on new drugs at ma ...... cations, and registry reports.
@en
P2093
P2860
P356
P1433
P1476
Information on new drugs at ma ...... cations, and registry reports.
@en
P2093
Anne Catharina Brockhaus
Beate Wieseler
Gregor Moritz
Heike Kölsch
Helmut Hörn
Katharina Biester
Kerstin Staeck
Michael Köhler
Natalie McGauran
Susanne Haag
P2860
P356
10.1136/BMJ.H796
P407
P577
2015-02-26T00:00:00Z